Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immatics NV (NQ: IMTX )

9.360 +0.010 (+0.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immatics NV

Immatics Announces Pricing of $150 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Proposed $150 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Second Quarter 2024 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Appoints Alise Reicin to Board of Directors
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
From https://immatics.com/
Via GlobeNewswire
Immatics Announces First Quarter 2024 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Full Year 2023 Financial Results and Corporate Update
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Pricing of $175 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Proposed Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Third Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
From https://immatics.com/
Via GlobeNewswire
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
From https://immatics.com/
Via GlobeNewswire
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Via ACCESSWIRE
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Second Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
From https://immatics.com/
Via GlobeNewswire
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
From https://immatics.com/
Via GlobeNewswire
Immatics Announces First Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
From https://immatics.com/
Via GlobeNewswire
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Full Year 2022 Financial Results and Corporate Update
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Third Quarter 2022 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
From https://immatics.com/
Via GlobeNewswire
Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
From https://immatics.com/
Via GlobeNewswire
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
From Bristol Myers Squibb
Via Business Wire
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
From Bristol Myers Squibb
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.